NCT02094599

A Study of the Abuse Potential of Dronabinol in Recreational Cannabinoid Users

A Single-dose, Double-blind, Double-dummy, Randomized, Placebo- and Active-controlled Crossover Study to Evaluate the Abuse Potential of Dronabinol Oral Solution in Recreational Cannabinoid Users

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 43 (actual)
• Sponsor: INSYS Therapeutics Inc · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The primary objective of this study is to evaluate the abuse potential of dronabinol oral solution in recreational cannabinoid users.

Detailed description

Following a four-day period for screening and qualification, there are five treatment visits with a minimum 8-day washout between treatments. Each participant will receive all treatments in a 5-way crossover design.

Conditions

• Drug Abuse, Medication

Interventions

Type	Name	Description
DRUG	Dronabinol 10 mg	Dronabinol at a strength equivalent to 10 mg provided in capsules or as an oral solution in syringes.
DRUG	Dronabinol 30 mg	Dronabinol at a strength equivalent to 30 mg provided in capsules or as an oral solution in syringes.
DRUG	Placebo	Matching placebo provided in capsules or as an oral solution in syringes.

Timeline

• Start date: 2014-02-01
• Primary completion: 2014-05-01
• Completion: 2014-05-01
• First posted: 2014-03-24
• Last updated: 2014-05-13

Locations

1 site across 1 country: Canada